loading

Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스

pulisher
Apr 04, 2025

Neurocrine Biosciences names new Chief Medical Officer By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences appoints new chief medical officer - The Pharma Letter

Apr 04, 2025
pulisher
Apr 04, 2025

UBS cuts Neurocrine Bio. stock target to $137, keeps Buy rating - Investing.com UK

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences names new Chief Medical Officer - Investing.com India

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Sanjay Keswani as Chief Medical Officer - Contract Pharma

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences Appoints Dr. Sanjay Keswani As Chief Medical Officer - MarketScreener

Apr 04, 2025
pulisher
Apr 04, 2025

Neurocrine Biosciences (NBIX) Appoints Dr. Sanjay Keswani as Chief Medical Officer - StreetInsider

Apr 04, 2025
pulisher
Apr 04, 2025

Pharma Veteran Behind Major Drug Approvals to Lead Neurocrine's Clinical Pipeline - Stock Titan

Apr 04, 2025
pulisher
Apr 04, 2025

Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $135 From $138, Maintains Hold Rating - MarketScreener

Apr 04, 2025
pulisher
Apr 03, 2025

Neurocrine Biosci stock hits 52-week low at $105.17 By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

UBS Lowers Price Target on Neurocrine Biosciences to $137 From $154, Keeps Buy Rating - MarketScreener

Apr 03, 2025
pulisher
Apr 03, 2025

Neurocrine Biosci stock hits 52-week low at $105.17 - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Cerebral Palsy Market Growth Projections 2024-2034: DelveInsight Analysis | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - The Globe and Mail

Apr 03, 2025
pulisher
Apr 02, 2025

Mitsubishi UFJ Trust & Banking Corp Sells 4,578 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Neurocrine Biosciences executive sells shares worth $266,024 - MSN

Apr 02, 2025
pulisher
Mar 31, 2025

New Data: INGREZZA Outperforms Competitors with Perfect Therapeutic Dose Rate - Stock Titan

Mar 31, 2025
pulisher
Mar 29, 2025

Supporting a Loved One Living with a Mental Health Condition and Tardive Dyskinesia - Main Street Media of Tennessee

Mar 29, 2025
pulisher
Mar 26, 2025

Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential - The Globe and Mail

Mar 26, 2025
pulisher
Mar 26, 2025

Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings) - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Ashland, Connectone Bancorp, Neurocrine Biosciences - TradingView

Mar 26, 2025
pulisher
Mar 25, 2025

Tardive Dyskinesia Treatment Market Expands with New Drug - openPR

Mar 25, 2025
pulisher
Mar 20, 2025

Neurocrine Biosciences debuts new data for effectiveness of Ingrezza - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

Neurocrine touts further positive trial results for Ingrezza - The Pharma Letter

Mar 20, 2025
pulisher
Mar 20, 2025

Neurocrine Biosciences (NBIX) Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA Capsules - StreetInsider.com

Mar 20, 2025
pulisher
Mar 20, 2025

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules - PR Newswire

Mar 20, 2025
pulisher
Mar 18, 2025

Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR

Mar 18, 2025
pulisher
Mar 18, 2025

Neurocrine at Stifel 2025 CNS Forum: Strategic Insights and Challenges - Investing.com

Mar 18, 2025
pulisher
Mar 18, 2025

Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance

Mar 18, 2025
pulisher
Mar 17, 2025

Is Neurocrine Biosciences, Inc. (NBIX) a Best Biotech Stock According to Billionaires? - Insider Monkey

Mar 17, 2025
pulisher
Mar 17, 2025

Neurocrine Biosciences Presents New Data From KINECT-HD Study Of Ingrezza - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules - The Victoria Advocate

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: INGREZZA Phase 3 Data Reveals Powerful Chorea Control Across All Body Regions - Stock Titan

Mar 17, 2025
pulisher
Mar 15, 2025

Neurocrine Biosciences chief legal officer sells $254,991 in stock - MSN

Mar 15, 2025
pulisher
Mar 14, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by StockNews.com - Defense World

Mar 14, 2025
pulisher
Mar 12, 2025

Schizophrenia Treatment Market Size Report 2034 | Novartis - openPR

Mar 12, 2025
pulisher
Mar 12, 2025

US Bancorp DE Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

RBC Capital cuts Neurocrine Bio. stock target to $139 from $148 - Investing.com India

Mar 12, 2025
pulisher
Mar 11, 2025

Trend Tracker for (NBIX) - Stock Traders Daily

Mar 11, 2025
pulisher
Mar 11, 2025

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum - PR Newswire

Mar 11, 2025
pulisher
Mar 11, 2025

RBC Cuts Price Target on Neurocrine Biosciences to $139 From $148, Keeps Sector Perform Rating - Marketscreener.com

Mar 11, 2025
pulisher
Mar 10, 2025

Smartleaf Asset Management LLC Purchases 146 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Neurocrine Biosciences, Inc. to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 09, 2025

Morgan Stanley Reiterates Overweight Rating for Neurocrine Biosciences (NASDAQ:NBIX) - Defense World

Mar 09, 2025
pulisher
Mar 07, 2025

Positive Growth Outlook for Neurocrine Biosciences Driven by Ingrezza and Crenessity Sales Projections - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Tardive Dyskinesia Treatment Market Size, Share & Future - openPR

Mar 07, 2025
pulisher
Mar 06, 2025

Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.

Mar 06, 2025
pulisher
Mar 06, 2025

Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions - Simply Wall St

Mar 06, 2025
pulisher
Mar 06, 2025

Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults - Yahoo Finance

Mar 06, 2025
pulisher
Mar 06, 2025

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating NBI-1140675 - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Neurocrine begins phase 1 study of new neurological drug By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Neurocrine begins phase 1 study of new neurological drug - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults - PR Newswire

Mar 05, 2025
pulisher
Mar 05, 2025

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Stock Retreats 25% But Earnings Haven't Escaped The Attention Of Investors - Simply Wall St

Mar 05, 2025
pulisher
Mar 05, 2025

Neurological Disorder Drugs Market Detailed In New Research - openPR

Mar 05, 2025
pulisher
Mar 04, 2025

Neurocrine Biosci stock hits 52-week low at $110.92 - Investing.com

Mar 04, 2025
$7.62
price down icon 6.62%
$90.92
price down icon 6.47%
$292.46
price down icon 4.85%
$30.06
price down icon 5.05%
$9.15
price down icon 5.86%
자본화:     |  볼륨(24시간):